These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19513106)

  • 41. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Educating men about vaginal microbicides: considerations from Kenya.
    Gitome SW; Kwena ZA; Harper CC; Cohen CR; Bukusi EA
    Cult Health Sex; 2020 Jun; 22(6):660-674. PubMed ID: 31241426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trial research in focus: why do so many clinical trials fail in IPF?
    Spagnolo P; Maher TM
    Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184
    [No Abstract]   [Full Text] [Related]  

  • 44. Who should go first in trials with scarce agents? The views of potential participants.
    Pentz RD; Flamm AL; Sugarman J; Cohen MZ; Xu Z; Herbst RS; Abbruzzese JL
    IRB; 2007; 29(4):1-6. PubMed ID: 17847620
    [No Abstract]   [Full Text] [Related]  

  • 45. Companies facing ethical issue as drugs are tested overseas.
    Kolata G
    N Y Times Web; 2004 Mar; ():A1, A15. PubMed ID: 15022671
    [No Abstract]   [Full Text] [Related]  

  • 46. Topical microbicides for preventing sexually transmitted infections.
    Obiero J; Ogongo P; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007961. PubMed ID: 33719075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
    Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
    Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. More ethical and more efficient clinical research: multiplex trial design.
    Keus F; van der Horst IC; Nijsten MW
    BMC Res Notes; 2014 Aug; 7():530. PubMed ID: 25125365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European Commission considers revisions to clinical trials directive.
    Mason E
    J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
    [No Abstract]   [Full Text] [Related]  

  • 50. Pazufloxacin Toyama Chemical Co.
    Johnson AP
    Curr Opin Investig Drugs; 2000 Sep; 1(1):52-7. PubMed ID: 11249595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 52. New microbicides enter trials in United States.
    AIDS Alert; 2005 Jan; 20(1):10-1. PubMed ID: 15717357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical research and the development of new drugs: issues for nurses.
    Holaday B; Mills DM
    Dimens Crit Care Nurs; 2004; 23(4):179-86. PubMed ID: 15273487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethical challenges in efficacy trials of vaginal microbicides for HIV prevention.
    de Zoysa I; Elias CJ; Bentley ME
    Am J Public Health; 1998 Apr; 88(4):571-5. PubMed ID: 9550996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discontinued drugs 2011: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1619-24. PubMed ID: 22917013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel clinical trial designs for the development of new antiretroviral agents.
    Mani N; Miller V;
    AIDS; 2012 Sep; 26(14):1847-8. PubMed ID: 22954760
    [No Abstract]   [Full Text] [Related]  

  • 57. Age discrimination in trials and treatment: old dogs and new tricks.
    Godlovitch G
    Monash Bioeth Rev; 2003 Jul; 22(3):66-77. PubMed ID: 14682321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials.
    Welch MJ; Lally R; Miller JE; Pittman S; Brodsky L; Caplan AL; Uhlenbrauck G; Louzao DM; Fischer JH; Wilfond B
    Clin Trials; 2015 Oct; 12(5):503-10. PubMed ID: 26374681
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.